First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma
Phase 1 other active
Quick answer
First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma for Relapsed/refractory B-cell aggressive lymphoma is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Relapsed/refractory B-cell aggressive lymphoma
- Phase
- Phase 1
- Modality
- other
- Status
- active